USA Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine), and with XEOMIN® (incobotulinumtoxinA) continuing to anchor its portfolio, Paolillo reflects on how Merz…
USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
USA You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of commercialisation reshape the pharmaceutical industry, Deborah Glasser reflects on how Sanofi is positioning its specialty care business for the next…
USA Access works when all pieces are in place. Hearing directly from patients about what diagnosis or how a treatment impacts their lives is meaningful to everyone involved Scott Weintraub, Head of US Business at Alexion, AstraZeneca Rare Disease, discusses how his experience across commercial leadership, strategy, and rare disease innovation…
USA Great success stories take time, great science, resilience. We built Denali with the goal of being one of those companies, not just surviving, but ultimately thriving. Ryan Watts is the co-founder and CEO of Denali Therapeutics, a South San Francisco-based biotech he founded after leading neuroscience research at Genentech. At…
Europe Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region Europe Head Dan Staner discusses the company’s long-term ambitions in specialty neurology, while also reflecting on the growing importance of…
USA Amy Adams stepped into the role of director of the National Institute of Neurological Disorders and Stroke (NINDS) at the beginning of the year after more than two decades within the National Institutes of Health (NIH) and serving as the institute’s acting deputy director. As a lifelong researcher, Dr Adams…
Taiwan Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho, Superintendent and Professor of Neurosurgery, explains how the institution operates as an integrated innovation platform, advancing cell and gene therapies,…
France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…
Taiwan Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing from Neurology Head for Taiwan and Hong Kong to regional leadership across Southeast Asia, she now steers both affiliates through…
USA Thomas Gibbs, EVP and President of Lundbeck US, details his three-decade industry journey before taking the reins of the enterprise’s most strategic market. Accounting for over half of global revenues, the US is a key contributor to Lundbeck’s patient impact and scientific delivery. Along with outlining the organisation’s Focused Innovator…
France This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at the forefront of neurology, he challenges simplified biological definitions, explains why risk must be stratified with rigour, and outlines a…
See our Cookie Privacy Policy Here
